期刊文献+

GST-HPV16E7融合蛋白的原核表达与纯化

Expression and Purification of GST-HPV16E7 Fusion Protein
下载PDF
导出
摘要 目的构建HPV16地方株E7基因原核表达质粒,使其在原核细胞中高效表达并进行纯化。方法将成都本地某宫颈癌患者所感染的HPV16E7全长片段插入原核表达载体pGEX-4T-1,构建重组子pGEX-4T-1-HPV16E7,转化宿主菌E.coliBL-21。经IPTG诱导表达,通过SDS-PAGE、Western blot分析证实蛋白表达的特异性。并用GST亲和层析法对融合蛋白进行纯化。结果该患者所感染的HPV16为东亚株,成功构建了原核表达载体pGEX-4T-1-HPV16E7并表达出GST-HPV16E7融合蛋白,证实了蛋白表达的特异性,并获得了GST-HPV16E7融合蛋白的纯品。结论成功表达、纯化了本地流行株GST-HPV16E7融合蛋白,为进一步研究HPV16E7蛋白的功能奠定了实验基础。 Objective To construct a recombinant prokaryotic expression vector efficiently expressing HPV16 E7 and purify GST-HPV16E7 fusion protein.Methods The HPV16 E7 gene obtained from a local cervical cancer patient was cloned into vector pGEX-4T-1,to generate the recombinant named as pGEX-4T-1-HPV16 E7.The recombinant plasmid was transformed into E.coli BL21.After inducing with IPTG the HPV16E7 fusion protein was analyzed by SDS-PAGE and Western blot.B-PER GST Fusion Protein Purification Kit was appkied to purify GST-HPV16E7 fusion protein.Results The recombinant plasmid pGEX-4T-1-HPV16 E7 was successfully constructed.Highly expressed and purified GST-HPV16E7 fusion protein was obtained.The specificity of fusion protein was verified by SDS-PAGE and Western blot.Conclusion GST-HPV16E7 fusion protein was successfully expressed and purified.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2009年第6期1123-1126,共4页 Journal of Sichuan University(Medical Sciences)
关键词 人乳头瘤病毒 E7 东亚株 原核表达 宫颈癌 Human papillomavirus E7 Prokaryotic cell expression Fusion protein Cervical cancer
  • 相关文献

参考文献7

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002. CA Cancer J Clin,2005,55(2):74-108.
  • 2Clifford G, Franeesehi S, Diaz M, et al. HPV type distribution in women with and without cervical neoplastic diseases. Vaccine, 2006,24,(supple 3) : S26-S34.
  • 3Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a recta-analysis update. Int J Caneer,2007,121 (3) :621-632.
  • 4Villa LL, Costa RL, Petta CA, etal. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women; a randomized double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol,2005,6(5):271-278.
  • 5Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 follow-up from a randomized control trial. Lancet,2006,367(9518):1247-1255.
  • 6Andersson S, Safari H, Mints M, et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer, 2005; 92 (12) :2195-2200.
  • 7Yamada T, Manos MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol,1997 ,71(3) :2463-2472.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部